NCGS, Inc.   Report issue

For profit Phase 2
Founded: Charleston SC United States (1984)

Organization Overview

First Clinical Trial
2014
NCT02025556
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

NCGS, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

fremanezumab (Ajovy) (1 trial)

xen1101 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Epilepsies, Partial (Phase 2)

Epilepsy (Phase 2)

Headache (Phase 2)

Migraine Disorders (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2